Romosozumab (brand name Evenity, Amgen/UCB) is a humanized monoclonal antibody targeting sclerostin, a protein secreted by osteocytes that inhibits the Wnt signaling pathway in osteoblasts. By neutralizing sclerostin, romosozumab simultaneously…
In the full monograph
- What it is, and how it works
- What the evidence shows — randomized trials, observational data, animal studies, graded and cited
- Dose, form, and timing
- What to expect, and how soon
- Who should be careful, and what to check first
- The verdict
MEMBERS
Read the full monograph
Members get every monograph in the library, the research assistant, and the stack tracker — with a 30-day money-back guarantee. Not ready? Start free with the Proven Supplements Starter Guide.